Eli Lilly & Co., which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets. The pharma's latest attempt to woo academics is perhaps not as flashy as the methods of competitors such as Pfizer Inc., Sanofi, and GlaxoSmithKline PLC – each of which is putting considerable resources behind gaining access to top-notch academic researchers worldwide. But Lilly plans to make up for that in simplicity and sheer volume. ( See "Back To School: Big Pharmas Test New Models For Tapping Academia," IN VIVO , February 2011 Also see "Back To School: Big Pharmas Test New Models For Tapping Academia " - In Vivo, 1 February, 2011..)
Since 2009 Lilly has operated a web portal that allows outside researchers to submit compounds for interrogation using Eli Lilly's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?